Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm

Fan Zhang, K. Craig Kent, Dai Yamanouchi, Yan Zhang, Kaori Kato, Shirling Tsai, Roman Nowygrod, Ann Marie Schmidt, Bo Liu

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

OBJECTIVE:: Rupture of abdominal aortic aneurysms (AAA) is a devastating event potentially preventable by therapies that inhibit growth of small aneurysms. Receptor of advanced glycation end products (RAGE) has been implicated in age related diseases including atherosclerosis and Alzheimer. Consequently, we explored whether RAGE may also contribute to the formation of AAAs. RESULTS:: Implicating a role for RAGE in AAA, we found the expression of RAGE and its ligand AGE were highly elevated in human aneurysm specimens as compared with normal aortic tissue. In a mouse model of AAA, RAGE gene deletion (knockout) dramatically reduced the incidence of AAA to 1/3 of control (AAAs in 75.0% of controls vs. 25.0% knockouts). Moreover, aortic diameter was markedly reduced in RAGE knockout animals versus controls. As to mechanism, we found that RAGE was coexpressed in AAA macrophages with MMP-9, a promoter of matrix degradation, which is known to induce AAA. In vitro, AGE induced the production of MMP-9 in macrophages in a dose-dependent manner while blocking RAGE signaling with a soluble AGE inhibitor prevented MMP-9 expression. In vivo, RAGE gene deficiency eliminated MMP-9 activity that was prevalent in aneurismal wall of the wild-type mice. CONCLUSIONS:: RAGE promotes the development of AAA by inducing MMP-9 expression. Blocking RAGE in a mouse aneurysm model has a dramatic inhibitory effect on the formation of aneurysms. These data suggest that larger animal and eventually human trials should be designed to test oral RAGE inhibitors and their potential to prevent progression of small aneurysms.

Original languageEnglish (US)
Pages (from-to)416-423
Number of pages8
JournalAnnals of Surgery
Volume250
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Abdominal Aortic Aneurysm
Aneurysm
Matrix Metalloproteinases
Therapeutics
Advanced Glycosylation End Product-Specific Receptor
Macrophages
Gene Knockout Techniques
Matrix Metalloproteinase Inhibitors
Gene Deletion
Rupture
Atherosclerosis
Ligands

ASJC Scopus subject areas

  • Surgery

Cite this

Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. / Zhang, Fan; Kent, K. Craig; Yamanouchi, Dai; Zhang, Yan; Kato, Kaori; Tsai, Shirling; Nowygrod, Roman; Schmidt, Ann Marie; Liu, Bo.

In: Annals of Surgery, Vol. 250, No. 3, 09.2009, p. 416-423.

Research output: Contribution to journalArticle

Zhang, F, Kent, KC, Yamanouchi, D, Zhang, Y, Kato, K, Tsai, S, Nowygrod, R, Schmidt, AM & Liu, B 2009, 'Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm', Annals of Surgery, vol. 250, no. 3, pp. 416-423. https://doi.org/10.1097/SLA.0b013e3181b41a18
Zhang, Fan ; Kent, K. Craig ; Yamanouchi, Dai ; Zhang, Yan ; Kato, Kaori ; Tsai, Shirling ; Nowygrod, Roman ; Schmidt, Ann Marie ; Liu, Bo. / Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. In: Annals of Surgery. 2009 ; Vol. 250, No. 3. pp. 416-423.
@article{036ec68d20f74e53854f3a13f519155c,
title = "Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm",
abstract = "OBJECTIVE:: Rupture of abdominal aortic aneurysms (AAA) is a devastating event potentially preventable by therapies that inhibit growth of small aneurysms. Receptor of advanced glycation end products (RAGE) has been implicated in age related diseases including atherosclerosis and Alzheimer. Consequently, we explored whether RAGE may also contribute to the formation of AAAs. RESULTS:: Implicating a role for RAGE in AAA, we found the expression of RAGE and its ligand AGE were highly elevated in human aneurysm specimens as compared with normal aortic tissue. In a mouse model of AAA, RAGE gene deletion (knockout) dramatically reduced the incidence of AAA to 1/3 of control (AAAs in 75.0{\%} of controls vs. 25.0{\%} knockouts). Moreover, aortic diameter was markedly reduced in RAGE knockout animals versus controls. As to mechanism, we found that RAGE was coexpressed in AAA macrophages with MMP-9, a promoter of matrix degradation, which is known to induce AAA. In vitro, AGE induced the production of MMP-9 in macrophages in a dose-dependent manner while blocking RAGE signaling with a soluble AGE inhibitor prevented MMP-9 expression. In vivo, RAGE gene deficiency eliminated MMP-9 activity that was prevalent in aneurismal wall of the wild-type mice. CONCLUSIONS:: RAGE promotes the development of AAA by inducing MMP-9 expression. Blocking RAGE in a mouse aneurysm model has a dramatic inhibitory effect on the formation of aneurysms. These data suggest that larger animal and eventually human trials should be designed to test oral RAGE inhibitors and their potential to prevent progression of small aneurysms.",
author = "Fan Zhang and Kent, {K. Craig} and Dai Yamanouchi and Yan Zhang and Kaori Kato and Shirling Tsai and Roman Nowygrod and Schmidt, {Ann Marie} and Bo Liu",
year = "2009",
month = "9",
doi = "10.1097/SLA.0b013e3181b41a18",
language = "English (US)",
volume = "250",
pages = "416--423",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm

AU - Zhang, Fan

AU - Kent, K. Craig

AU - Yamanouchi, Dai

AU - Zhang, Yan

AU - Kato, Kaori

AU - Tsai, Shirling

AU - Nowygrod, Roman

AU - Schmidt, Ann Marie

AU - Liu, Bo

PY - 2009/9

Y1 - 2009/9

N2 - OBJECTIVE:: Rupture of abdominal aortic aneurysms (AAA) is a devastating event potentially preventable by therapies that inhibit growth of small aneurysms. Receptor of advanced glycation end products (RAGE) has been implicated in age related diseases including atherosclerosis and Alzheimer. Consequently, we explored whether RAGE may also contribute to the formation of AAAs. RESULTS:: Implicating a role for RAGE in AAA, we found the expression of RAGE and its ligand AGE were highly elevated in human aneurysm specimens as compared with normal aortic tissue. In a mouse model of AAA, RAGE gene deletion (knockout) dramatically reduced the incidence of AAA to 1/3 of control (AAAs in 75.0% of controls vs. 25.0% knockouts). Moreover, aortic diameter was markedly reduced in RAGE knockout animals versus controls. As to mechanism, we found that RAGE was coexpressed in AAA macrophages with MMP-9, a promoter of matrix degradation, which is known to induce AAA. In vitro, AGE induced the production of MMP-9 in macrophages in a dose-dependent manner while blocking RAGE signaling with a soluble AGE inhibitor prevented MMP-9 expression. In vivo, RAGE gene deficiency eliminated MMP-9 activity that was prevalent in aneurismal wall of the wild-type mice. CONCLUSIONS:: RAGE promotes the development of AAA by inducing MMP-9 expression. Blocking RAGE in a mouse aneurysm model has a dramatic inhibitory effect on the formation of aneurysms. These data suggest that larger animal and eventually human trials should be designed to test oral RAGE inhibitors and their potential to prevent progression of small aneurysms.

AB - OBJECTIVE:: Rupture of abdominal aortic aneurysms (AAA) is a devastating event potentially preventable by therapies that inhibit growth of small aneurysms. Receptor of advanced glycation end products (RAGE) has been implicated in age related diseases including atherosclerosis and Alzheimer. Consequently, we explored whether RAGE may also contribute to the formation of AAAs. RESULTS:: Implicating a role for RAGE in AAA, we found the expression of RAGE and its ligand AGE were highly elevated in human aneurysm specimens as compared with normal aortic tissue. In a mouse model of AAA, RAGE gene deletion (knockout) dramatically reduced the incidence of AAA to 1/3 of control (AAAs in 75.0% of controls vs. 25.0% knockouts). Moreover, aortic diameter was markedly reduced in RAGE knockout animals versus controls. As to mechanism, we found that RAGE was coexpressed in AAA macrophages with MMP-9, a promoter of matrix degradation, which is known to induce AAA. In vitro, AGE induced the production of MMP-9 in macrophages in a dose-dependent manner while blocking RAGE signaling with a soluble AGE inhibitor prevented MMP-9 expression. In vivo, RAGE gene deficiency eliminated MMP-9 activity that was prevalent in aneurismal wall of the wild-type mice. CONCLUSIONS:: RAGE promotes the development of AAA by inducing MMP-9 expression. Blocking RAGE in a mouse aneurysm model has a dramatic inhibitory effect on the formation of aneurysms. These data suggest that larger animal and eventually human trials should be designed to test oral RAGE inhibitors and their potential to prevent progression of small aneurysms.

UR - http://www.scopus.com/inward/record.url?scp=70249125867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249125867&partnerID=8YFLogxK

U2 - 10.1097/SLA.0b013e3181b41a18

DO - 10.1097/SLA.0b013e3181b41a18

M3 - Article

C2 - 19652591

AN - SCOPUS:70249125867

VL - 250

SP - 416

EP - 423

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 3

ER -